… Our pooled analysis indicated that neoadjuvant EGFR-TKI therapy may provide a feasible
treatment modality for patients with resectable or potentially resectable EGFR-mutant NSCLC, …

… NSCLC provides an expanded dataset for analysis. This paper describes an … EGFR TKIs
in patients with EGFR mutation-positive NSCLC, and reports the results of a pooled analysis of …

… In conclusion, our pooled analysis demonstrated that EGFR-TKIs are an effective … EGFR
mutations. Therefore, we emphasize that patients with NSCLC should be tested for EGFR …

… suggest that ethnic differences may affect the clinical manifestation of ILD in unselected
patients treated with EGFR-TKIs. Our pooled analysis of EGFR-TKI treatment in EGFR mutation-…

… It is, therefore, only possible to estimate the proportion of patients included in this analysis
who received an EGFR TKI as first-line treatment. The estimated proportion of patients in this …

… a grade 3 ILD from our pooled analysis was a male smoker with an EGFR mutation [47]. …
for EGFR-mutant NSCLC, our results confirm that acquired resistance to EGFR TKI therapy is …

… Here, in order to assess outcomes in a larger cohort, we report a combined analysis of three
phase IIIb studies of afatinib in EGFR TKI-naïve patients with EGFRm+ NSCLC treated in a …

… harbor uncommon EGFR mutations that have variable sensitivity to different EGFR TKIs.
However, … The main resistance mechanism of EGFR-TKIs is the emergence of secondary EGFR-…

… By contrast, the survival data of our pooled analyses were similar to that of anlotinib, another
oral TKI targeting VEGFR, PDGFR, FGFR, and c-Kit. [47] The ALTER 0303 study [48] (a …

… study aimed to (1) provide an up-to-date literature analysis evaluating the efficacy and safety
of individual regimens for brain-metastatic EGFR-… on data from large-population registries. …